Usefulness of compounds with monacolin K in a case of statins intolerance
Clin Investig Arterioscler. 2018 Nov-Dec;30(6):268-270.
doi: 10.1016/j.arteri.2018.06.003.
Epub 2018 Oct 9.
[Article in
English,
Spanish]
Affiliations
- 1 Internal Medicine, Lipids Unit, Gregorio Marañón University Hospital, Madrid, Spain.
- 2 Internal Medicine, Lipids Unit, Gregorio Marañón University Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; Instituto de Investigaciones Sanitarias Gregorio Marañón, Madrid, Spain.
- 3 Internal Medicine, Lipids Unit, Gregorio Marañón University Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; Instituto de Investigaciones Sanitarias Gregorio Marañón, Madrid, Spain. Electronic address: laalvarez@med.ucm.es.
Abstract
Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk.
Keywords:
Inhibidores de PCSK9; Intolerancia a las estatinas; Monacolin K; Monacolina K; PCSK9 inhibitors; Statins intolerance.
Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Anticholesteremic Agents / administration & dosage*
-
Biological Products / administration & dosage
-
Cholesterol, LDL / blood
-
Drug Therapy, Combination
-
Ezetimibe / administration & dosage*
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hyperlipoproteinemia Type II / drug therapy*
-
Lovastatin / administration & dosage*
-
Middle Aged
-
PCSK9 Inhibitors
Substances
-
Anticholesteremic Agents
-
Biological Products
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
PCSK9 Inhibitors
-
red yeast rice
-
Lovastatin
-
PCSK9 protein, human
-
Ezetimibe